Početna stranicaHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Preth. zaklj. cijena
25,85 €
Dnevni raspon
25,67 € - 25,67 €
Godišnji raspon
19,52 € - 36,69 €
Tržišna kapitalizacija
3,58 mlr. USD
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(USD) | ožu 2024.info | Godišnja promjena |
---|---|---|
Prihod | — | — |
Operativni troškovi | 126,19 mil. | 28,63 % |
Neto dohodak | −125,30 mil. | −357,42 % |
Neto profitabilnost | — | — |
Zarada po dionici | −1,02 | −326,67 % |
EBITDA | −121,67 mil. | −339,34 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(USD) | ožu 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 520,91 mil. | 8,30 % |
Ukupna imovina | 955,15 mil. | 7,16 % |
Ukupne obveze | 459,74 mil. | 7,87 % |
Ukupni kapital | 495,40 mil. | — |
Dionice u optjecaju | 124,20 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 6,63 | — |
Povrat imovine | −39,90 % | — |
Povrat kapitala | −43,18 % | — |
Tok novca
Neto promjena novca
(USD) | ožu 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | −125,30 mil. | −357,42 % |
Gotovina od poslovanja | −92,38 mil. | −191,68 % |
Gotovina iz ulaganja | −268,94 mil. | −645,70 % |
Gotovina iz financiranja | 430,78 mil. | 82.741,73 % |
Neto promjena novca | 69,49 mil. | 203,27 % |
Slobodan tok novca | −91,82 mil. | −262,49 % |
Više
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Glavni izvršni direktor
Osnovano
1. sij 2004.
Web-lokacija
Zaposlenici
525